Mylan Specialty L.P., a subsidiary of Mylan Inc. (MYL), and Pfizer Inc. (PFE) announced a license agreement, under which Pfizer will obtain the exclusive rights to market and sell EpiPen Injection 0.3/0.15mg in Japan.
These products, known in the U.S. as EpiPen (epinephrine) 0.3mg and EpiPen Jr (epinephrine) 0.15mg Auto-Injectors, are for self-administration for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise or unknown triggers. EpiPen Injection is the only approved epinephrine auto-injector in Japan.
As per the terms of the agreement, the exclusive rights to market and sell the next-generation EpiPen Injection in Japan will be transferred to Pfizer from Mylan Seiyaku. The next-generation EpiPen Injection and EpiPen Auto-Injector are currently available in Japan, the U.S., Canada, South Africa, Australia and certain European countries.
The financial terms of the agreement were not disclosed.
For comments and feedback: editorial@rttnews.com